A preliminary study of PEFR monitoring in patients with chronic cough.
It is important to make a differential diagnosis of cough variant asthma in patients with chronic cough. To examine whether or not peak expiratory flow rate (PEFR) is useful for the differential diagnosis of cough variant asthma in such patients, diurnal variation rates of PEFR were calculated in 23 patients who presented with dry cough lasting four or more weeks and who showed no abnormalities on chest radiographs. None of the patients had wheezes, and pulmonary function testing at the time of visit to the hospital revealed no abnormalities. During the control period, the mean diurnal variation rate of PEFR in 23 patients was 16.3 +/- 7.9%. Six, nine and eight patients had PEFR diurnal variations rates of <10% (Group 1), 10-19% (Group 2), and > or = 20% (Group 3), respectively. At week 3 of treatment with bronchodilators, only Group 3 showed a significant decrease in PEFR diurnal variation rate from 25.7% to 10.1%. The cough score decreased significantly in Group 3 only. These patients had enhanced bronchial hyperresponsiveness and showed eosinophils in induced sputum, leading to the diagnosis of cough variant asthma (CVA). After making the diagnosis of CVA, an inhaled corticosteroid or a Th2 cytokine production inhibitor suplatast tosilate was administered to patients; consequently, they showed no recurrence of cough. PEFR monitoring allowed the detection of morning dip and was suggested to be potentially useful for the differential diagnosis of cough variant asthma in patients with chronic cough.
Sano
T
T
Department of Pulmonary Medicine, Tokushima Prefectural Central Hospital, Kuramoto-cho 1-10-3, Tokushima, Tokushima 770-8539, Japan. tmkksano@mb2.tcn.ne.jp
Ueda
H
H
Bando
H
H
D000328:Adult; D000368:Aged; D001249:Asthma / Q000175:diagnosis / Q000503:physiopathology; D016535:Bronchial Hyperreactivity / Q000175:diagnosis / Q000503:physiopathology; D002908:Chronic Disease; D002940:Circadian Rhythm / Q000502:physiology; D003371:Cough / Q000175:diagnosis / Q000503:physiopathology*; D003937:Diagnosis, Differential; D004804:Eosinophils / Q000378:metabolism; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate / Q000502:physiology*; D012129:Respiratory Function Tests
D007073:Immunoglobulin E
Br J Dis Chest. 1977 Apr;71(2):73-86
861158
N Engl J Med. 1975 Mar 13;292(11):555-9
1110670
Chest. 1997 Sep;112(3):862-3
9315837
Arerugi. 1982 Oct;31(10):1074-6
7168651
Am Rev Respir Dis. 1991 Feb;143(2):323-30
1990947
Lancet. 2000 Jul 22;356(9226):273-8
11071181
Thorax. 1980 Oct;35(10):732-8
7466721
Chest. 1998 Aug;114(2 Suppl Managing):133S-181S
9725800
Lancet. 1989 Jun 17;1(8651):1346-8
2567371
Eur J Clin Pharmacol. 2002 Jun;58(3):171-6
12107601
Eur J Respir Dis. 1980 Oct;61(5):298-302
7193594
J Allergy Clin Immunol. 2003 Jan;111(1):197-8
12532121
Am Rev Respir Dis. 1990 Mar;141(3):640-7
2178528
Thorax. 1982 Jun;37(6):423-9
6890243
Respiration. 1980;40(3):128-35
7444191
Lung. 2003;181(4):227-35
14692563
N Engl J Med. 1979 Mar 22;300(12):633-7
763286
Life Sci. 1995;56(19):1647-54
7723593
J Asthma. 1994;31(6):463-72
7961323
J Asthma. 1998;35(2):225-9
9576149
Chest. 1972 Mar;61(3):262-6
5021171
Thorax. 1998 Nov;53(11):953-6
10193394
Jpn J Pharmacol. 1993 Jan;61(1):31-9
8382323
Agents Actions Suppl. 1991;34:369-78
1665310
Br J Dis Chest. 1979 Oct;73(4):357-66
576035